Asian Spectator


The Times

.

Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes

  • UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
  • In a phase 2 trial in Chinese people with type 2 diabetes, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean body weight reduction of up to 9.8% after 24 weeks, showing improvements relative to placebo and semaglutide 1 mg
  • The safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical trials with triple-G agonists.

Magazine

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

Why Early Protection of Intellectual Assets is Critical

For many businesses, intellectual assets are among the most valuable things they own, yet they're often the last to receive formal legal protection. A brand name or a proprietary process can represe...

Konservasi gaya lama tak efektif: Pemulihan Aceh perlu warga dengan ekonomi yang merawat hutan

shutterstock(Manthofana/Shutterstock)● Peminggiran warga dari konservasi hutan Lingga Isaq menjadi salah satu faktor yang memperparah dampak bencana.● Pertanian monokultur dan tambang emas...

hacklink hack forum hacklink film izle hacklink z-libraryGrandpashabetgrandpashabetDeneme bonusu veren siteler 2026Deneme bonusu veren siteler 2026Grandpashabetmarsbahis giriş爱思助手下载aresbettelegram下载jojobet girişgrandpashabetgrandpashabet twiter xbetparktelegram webroyalbet girişcasibomjojobetdeneme bonususlot sitelerideneme bonusujojobetjojobetjojobetjojobetcasibom